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Abstract: Herein, the synthesis and pharmacological evaluation of 13 novel 
compounds, designed as potential heterobivalent ligands for μ-opioid receptor 
(MOR) and dopamine D2 receptors (D2DAR), are reported. The compounds 
consisted of anilido piperidine and N-aryl piperazine moieties, joined by a 
variable-length methylene linker. The two moieties represent MOR and 
D2DAR pharmacophores, respectively. The synthesis encompassed four steps, 
securing the final products in 28–42 % overall yields. The approach has a con-
siderable synthetic potential, providing access to various related structures. 
Pharmacological tests involved in vitro competitive assay for D2DAR using 
[3H] spiperon, as a standard radioligand, and in vivo antinociceptive tests for 
MOR. The measured dopamine affinities were modest to low, while antinocic-
eptive activity was completely absent. Therefore, the compounds of the general 
structure prepared in this research are unlikely to be useful as opioid–dopamine 
receptor heterobivalent ligands. 
Keywords: piperidine; piperazine; heterobivalent; opioids; analgesics; dopami-
nergic. 
INTRODUCTION 
Pain relief is one of the major goals of modern drug development. Currently, 
there are several pharmacologically distinct groups of drugs, acting on various 
types and intensities of pain. Two groups of drugs are particularly prominent, i.e. 
NSAIDs (non-steroidal anti-inflammatory drugs) and opioids. While the former 
are highly useful in the treatment of many milder to moderate painful conditions, 
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opioids are indispensable for alleviating severe acute and chronic pain, especially 
in clinical settings.1 
Almost all approved opioids are ΜOR agonists, including morphine and its 
numerous semi-synthetic derivatives, as well as many structurally diverse syn-
thetic compounds. Among the synthetic ΜOR opioids, especially potent are anil-
ido piperidines, including the clinically significant drugs fentanyl (Actiq®, Abs-
tral®), sufentanil (Sufenta®), alfentanil (Alfenta®) and remifentanil (Ultiva®).  
Agonists of κ- and δ-opioid receptors (KOR and DOR, respectively) have 
minimal medical use, due to the low potency and/or side effects. However, the 
side effects of the MOR agonists are also quite severe, often causing acute life-
threatening respiratory depression as well as tolerance and addiction. 
Extensive experimental results have indicated that opioid receptors in the 
central nervous system may form homodimers.2,3 In addition, heterodimerization 
was inferred, primarily involving MOR and other opioid or non-opioid receptors. 
The main tools in these have been numerous homo and heterobivalent ligands, 
designed as specific pharmacological probes. Some of the representative hetero-
dimers include ΜOR/DOR,2 ΜOR/ΚOR,4 ΜOR/cannabinoid receptor type 1,5 
ΜOR/metabotropic glutamate receptor type 5,6 ΜOR/chemokine-receptor type 
5,7 ΜOR/NSAIDs8 and ΜOR/N-type Ca2+ channels.9 
It is known that opioid and dopamine receptors are co-distributed in many 
brain tissues, indicating possible functional interaction.10,11 Thus, there is signif-
icant evidence of opioid-dopaminergic cross regulation, especially in reward pro-
cesses associated with opioid addiction. Five dopamine receptor subtypes are 
known to exist in the CNS, divided into two groups: D1likeDAR (D1DAR and 
D5DAR) and D2likeDAR (D2DAR, D3DAR and D4DAR). Evidence of direct 
interactions between D2likeDAR and MOR was shown in several in vivo and in 
vitro tests.12 Recently, reported series of compounds were designed to act as 
bivalent ligands for MOR/D2likeDAR heterodimers, especially for D2DAR/ 
/MOR and D4DAR/MOR heterodimers the existence of which was observed exp-
erimentally.13  
The D2DAR and ΜOR system, whether it exists in the form of heterodimers 
or monomers, represents a potential target in the treatment of opioid addiction. 
Therefore, a series of potential heterobivalent opioid–dopamine receptor ligands 
were designed and synthesized as a part of ongoing synthetic and pharmaco-
logical research in functionalized heterocycles.14 The compounds included the 
both pharmacophores, joined by methylene linkers of various lengths (general 
structure 1, Fig. 1). The fentanyl scaffold (i.e., anilido piperidine moiety) was 
selected as ΜOR pharmacophore because of the known high affinity for this 
receptor type. Likewise, the N-aryl piperazine moiety represents a well known 
structural motif with high affinity for D2DAR receptors.15,16 
________________________________________________________________________________________________________________________Available on line at www.shd.org.rs/JSCS/
(CC) 2020 SCS.
 HETEROBIVALENT OPIOID-DOPAMINE RECEPTOR LIGANDS 713 
 




Unless otherwise stated, all solvents were freshly distilled under Ar prior to use. All 
reagents were purchased from a commercial vendor and used as supplied.  
1H- and 13C-NMR spectra were recorded on Bruker Avance III spectrometer, at 500 
MHz for the proton (1H) and at 126 MHz for the carbon (13C). Chemical shifts are given in 
parts per million from tetramethylsilane (TMS) as the internal standard in CDCl3. 2D-NMR 
spectra (HSQC) were recorded at 500 MHz. The coupling constants (J) are reported in Hz. 
Unless otherwise stated, all spectra were recorded at 25 °C. High resolution mass spectra 
(HRMS) were obtained with a heated ESI (HESI)-Orbitrap spectrometer.  
All reactions were monitored by thin layer chromatography (TLC). Flash and dry- 
-column flash chromatography were realized using silica gel (10–18 or 18–32 μm, ICN- 
-Woelm). Melting points were obtained at a heating rate of 4 °C min-1 and are uncorrected.  
IR spectra were recorded by using a Thermo Scientific Nicolet 6700 Fourier-transform 
spectrometer operated in the ATR mode.  
The structures of all new compounds were determined by 1D-, 2D-NMR and IR spectro-
scopy. The structures of the three final compounds were additionally confirmed by high-
resolution mass spectrometry (HRMS). 
Analytical and spectral data are given in Supplementary material to this paper. 
Syntheses 
General procedure for the synthesis of aryl piperazino carboxamides 3a–m. To a mag-
netically stirred solution of aryl piperazine hydrochloride 2a–c (3.5 mmol) in CH2Cl2 (10 
mL), Et3N (4.2 mmol) and ω-bromo-acylchloride (5.25 mmol) were added at 0 °C. The mix-
ture was then allowed to stir. Reaction was monitored by TLC, with mixture of CH2Cl2– 
–MeOH (95:5) as the eluent. After 40 min of stirring at 0 °C, the mixture was stirred for an 
additional l20 min at 25 °C to complete the reaction. MeOH (10 mL) was then added, and the 
mixture was concentrated on a rotary evaporator. A solution of K2CO3 (1.5 M) was added (pH 
≈11) and the mixture was extracted with 2×25 mL of CH2Cl2. Organic layers were collected 
and concentrated on a rotary evaporator. The crude product was used in the next step without 
further purification. 
General procedure for the synthesis of aryl piperazino carboxamide-anilino piperidine 
5a–m. To a magnetically stirred solution of anilino piperidine 4 (1.6 mmol) and K2CO3 (4.08 
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mmol) in MeCN (12 mL), aryl piperazino carboxamide 3a–m (2.04 mmol) was added. The 
mixture was allowed to stir at 70 °C. Reaction was monitored by TLC, with mixture of 
CH2Cl2–MeOH (95:5) as an eluent. The reaction was completed after 8 h of reflux and addit-
ional stirring for 10 h at 25 °C. The mixture was then concentrated on a rotary evaporator. 
CH2Cl2 (50 mL) was added and the mixture was extracted with 2×25 mL of brine. The org-
anic phase was concentrated on a rotary evaporator. The crude product was purified by dry- 
-column flash chromatography (SiO2; CH2Cl2/MeOH 10:0:95:5). 
General procedure for the synthesis of aryl piperazino-anilino piperidine adducts 6a–m. 
To a magnetically stirred suspension of aryl piperazino-anilino piperidine adduct 5a–m (1.0 
mmol) in dry THF (12 mL), 1M solution of BH3 in dry THF (2.5 mmol) was added at 0 °C. 
The mixture was then allowed to stir at 25 °C. After the spontaneous boiling had stopped, the 
mixture was heated at 70 °C. Reaction was monitored by TLC, with mixture of CH2Cl2– 
–MeOH (95:5) as the eluent. After 4 h of reflux, water (1 mL) was added dropwise, followed 
with addition of 5.5 M HCl (2 mL) at 25 °C. The reflux was continued for an additional 4 h. 
The mixture was then concentrated on a rotary evaporator. CH2Cl2 (50 mL) was added, the 
layers were separated, and the organic phase was washed with 2×25 mL of brine. The organic 
phase was concentrated on a rotary evaporator. The crude product was used in the next step 
without further purification. 
General procedure for the synthesis of aryl piperazino-anilido piperidine adducts 1a–m. 
To a magnetically stirred solution of aryl piperazino-anilino piperidine adducts 6a–m (0.6 
mmol) in CH2Cl2 (10 mL), Et3N (0.9 mmol) followed by addition of propionyl chloride 
(EtCOCl, 1.8 mmol) were added. Mixture was then allowed to stir at 25 °C. Reaction was 
monitored by TLC, with mixture of CH2Cl2–MeOH (95:5) as the eluent. After 3.5 h, MeOH 
(10 mL) was added, and the mixture was concentrated on a rotary evaporator. A solution of 
K2CO3 (1.5 M) was added (pH ≈11) and the mixture was extracted with 2×25 mL of CH2Cl2. 
The organic layers were collected, washed with 2×25 mL of brine, and concentrated on a rot-
ary evaporator. The crude product was purified by dry-column flash chromatography (SiO2; 
CH2Cl2–MeOH, 10:0 to 95:5). 
Biological assays 
Membrane preparation. The preparation of rat caudate nuclei synaptosomal membranes 
for D2DAR binding experiments was described in detail in previous publications.17,18 
Radioligand binding assay. The [3H] spiperone binding assay was performed in 4 mM 
MgCl2, 1.5 mM CaCl2, 5 mM KCl, 120 mM NaCl, 25 mM Tris–HCl solution, pH 7.4, at a 
membrane protein concentration of 0.7 mg mL-1 at 37 °C for 10 min in a total volume of 0.4 
mL of the incubation mixture. Binding of the radioligand to the 5-HT2a receptors was pre-
vented by 50 μM ketanserin. The Ki values of the tested compounds were determined by 
competition binding at 0.2 nM of the radioligand and eight to ten different concentrations of 
each compound (10-4 to 10-10 M). Nonspecific binding was measured in the presence of 10 
µM spiperone. The reaction was terminated by rapid filtration through Whatman GF/C filters, 
which were further washed three times with 3.0 mL of ice-cold incubation buffer. Each point 
was determined in triplicate. The retained radioactivity was measured by introducing the dry 
filters into 3 mL of toluene-based scintillation liquid and counting in a 1219 Rackbeta Wallac 
scintillation counter (EG & G Wallac, Turku, Finland) at an efficiency of 51–55 % for tritium. 
The results were analyzed by nonlinear curve fitting of the inhibition curves of the compounds 
utilizing the Graph-Pad Prism program.4,6 Hill slope coefficients were fixed to unity during 
the calculation. 
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Animal preparation. The study was carried out on 75 adult male Wistar rats (200–250 g) 
obtained from the Military Medical Academy (Belgrade, Serbia). The animals were housed in 
groups of three per cage (42.5 cm×27 cm×19 cm) under standard conditions of temperature 
(22±1 °C), relative humidity (60 %) and a 12 h light/dark cycle, with lights on at 8:00 a.m. 
Food and water were freely available, except during the experimental procedures. The animals 
were fed standard rat pellets obtained from the Veterinary Institute Subotica, Serbia. The exp-
eriments were conducted by the same experimenter on consecutive days, always at the same 
time of the day, between 8:00 a.m. and 2:00 p.m., to avoid diurnal variation in the behavioral 
tests. The animals were unrestrained during testing. Each animal was used only once and 
killed at the end of the experiments by an intraperitoneal (i.p.) injection of sodium thiopental 
(200 mg/kg). Prior to each experiment, the animals were habituated to the handling and exp-
erimental procedure for three consecutive days. The antinociceptive activity was determined 
by tail-immersion.19 
All compounds were dissolved in saline and injected i.p. in a final volume of 2 ml kg-1.19  
Tail-immersion test. The rat was placed in a cylindrical rat holder with its tail hanging 
freely outside the cage. The distal 5 cm of the tail was immersed in a warm water bath (55±0.5 
°C) and the time for tail-withdrawal was measured as response latency. To minimize tissue 
damage by repeated testing, a 10-s cutoff time was imposed for all animals that failed to res-
pond to the stimulus. This means that the maximal duration of a single exposure of rat tail to 
hot water was 10 s. Pre-drug response latency was obtained 5 min before i.p. drug adminis-
tration. Post-drug response latency was measured after i.p. administration of the test com-
pound at 5, 10, 15, 20, etc. min. To test whether drug injection in rats has effect on the tail 
immersion latency, the t-test for paired values was used.20 A P value of less than 0.05 was 
considered statistically significant.  
RESULTS AND DISCUSSION 
The initial research of the D2DAR/ΜOR heterobivalent ligands involved the 
synthesis of only three compounds of general formula 1, as proof of the synthetic 
concept.14  
Herein, the optimized synthesis of 13 novel compounds of the general for-
mula 1, having 3 to 7 methylene groups in the linker, were synthesized according 
to the published procedure,14 (Scheme 1). 2-Methoxyphenylpiperazine was 
chosen here rather than 3-methoxyphenylpiperazine16, since it is a more abun-
dant structural unit in D2-like-DAR pharmacophores.  
Additionally, 15 compounds as D2DAR and/or  ΜOR ligands were assayed 
including the previously prepared compounds 1n and 1o14 (Table I).  
The synthesis encompassed 4 steps (Scheme 1). Commercial N-aryl 
piperazines 2a–c were acylated with 3-bromopropanoyl chloride or higher homo-
logues, furnishing ω-bromo amides 3a–m, almost quantitatively. The compounds 
were then reacted with anilinopiperidine 4 providing N-alkylated piperidines 5a–m 
in moderate to good yields. Although the alkylation of the piperidine nitrogen 
predominated, small amounts of N,N-dialkylated products were also formed, and 
removed chromatographically. It is noteworthy that the dialkylation was unexp-
ected, because of the estimated weak nucleophilicity of the anilino nitrogen. The 
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subsequent borane reduction of the tertiary carboxamido group proceeded cleanly 
to amines 6a–m. The final propanamides 1a–m were obtained by direct N-pro-
pionylation (Table I). The overall synthetic approach is concise and practical, 
affording structurally diverse final products in 28–42 % overall yields, depending 
on the reactant structures. 
 
Scheme 1. Synthetic route to the potential MOR/D2DAR heterobivalent ligands 1a–1m. 
The prepared propanamides, having linkers of various lengths, are potential 
ligands of D2DAR, ΜOR as well as D2DAR/MOR heterodimers. In this res-
earch, the pharmacological testing was limited to in vitro assaying of D2DAR 
binding as well as estimating the opioid activity using in vivo rodent tests. 
The affinity of propanamides 1a–m towards D2DAR was assessed by a com-
petitive displacement assay using [3H] spiperon as the standard radioligand. The 
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results are summarized in Table I. Compounds 1a–c, possessing three methylene 
groups in the linker, displayed moderate D2DAR affinity. Substituents on the 
piperazine aryl group did not play a significant role (Table I, entries 1–3). How-
ever, longer linkers, having 4–7 methylene groups, strongly reduce the affinity 
(Table I, entries 4–15). Thus, it is evident that most ligands of the general struc-
ture 1 cannot form stable complexes with D2DAR, likely because they cannot fit 
into the binding site of the receptor. More detailed insight into D2DAR–ligand 
interactions could be gained from future docking studies, using the known 
D2DAR crystalline structure.21 
TABLE I. Structure and pharmacological activity of the ligands of the general formula 1 
Entry Cmpd. Ar n Yield
a
% 
Binding for D2DAR receptor 
Ki D2DAR, nMb 
Opioid 
activityc 
1 1a Ph 2 32 869 Inactivee 
2 1b 2-OMeC6H4 2 31 800 Inactivee 
3 1c 2,3-Cl2C6H3 2 28 594 Inactivee 
4 1d 2-OMeC6H4 3 37 7992 Inactivee 
5 1e Ph 4 37 7083 Inactivee 
6 1f 2-OMeC6H4 4 32 4436 Inactivee 
7 1g 2,3-Cl2C6H3 4 30 2376 Inactivee 
8 1h Ph 5 40 8105 Inactivee 
9 1i 2-OMeC6H4 5 34 3778 Inactivee 
10 1j 2,3-Cl2C6H3 5 30 1500 Inactivee 
11 1k Ph 6 42 1853 Inactivee 
12 1l 2-OMeC6H4 6 35 5454 Inactivee 
13 1m 2,3-Cl2C6H3 6 32 5326 Inactivee 
14d 1n Ph 3 – 1357 Inactivee 
15d 1o 2,3-Cl2C6H3 3 – 6956 Inactivee 
16 Haloperidol – – – 5.3 – 
aOverall isolated yield for four steps; bvalues are the means of three independent experiments performed in 
triplicate; cexamined in vivo in rats by the rat-tail immersion test; dprepared in previous research;14 ein doses up 
to 2 mg kg-1 
Opioid activity of propanamides 1a–m was estimated using in vivo tests, 
since these tests provide more clinically reliable information about the analgesic 
activity of ligands in animal models than in vitro experiments in the laboratory. 
The complete absence of opioid activity (Table I), does not rule out affinity to 
MOR, as the ligands may not be able to reach the MOR due to physicochemical 
characteristics and/or metabolism. Therefore, their opioid affinity requires in 
vitro reassessment, in order to correlate it to the future molecular docking studies. 
It should be noted that such theoretical studies could be performed with good 
accuracy because the crystalline structure of MOR is known.3,22,23 
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CONCLUSION 
The general procedure presented in this paper is useful for the synthesis of 
structurally diverse, heterobifunctional compounds. Thus, any two secondary 
amino groups can be joined selectively, using various linkers. Besides polymeth-
ylene chains, the linkers may include oligo (ethylene glycol) units as well as 
more complex groups. The obtained heterobifunctional compounds are potential 
bivalent receptor ligands, and may have numerous applications in bioconjugation 
chemistry.24 The synthesized compounds were inactive as bidentate ligands, as 
no antinociceptive activity was observed. It is practically certain that the structure 
of the ligands prevented effective binding to the receptors. However, ligand 
structural requirements for effective binding can only be deduced from the ext-
ensive ligand docking, corroborated by experimental results. 
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И З В О Д  
ЛИГАНДИ КОЈИ САДРЖЕ ФАРМАКОФОРЕ ЗА μ-ОПИОИДНЕ И D2 ДОПАМИНСКЕ 
РЕЦЕПТОРЕ: СИНТЕЗА И ФАРМАКОЛОШКО ИСПИТИВАЊЕ 
ИВАНА И. ЈЕВТИЋ1, ЈЕЛЕНА З. ПЕЊИШЕВИЋ1, КАТАРИНА Р. САВИЋ-ВУЈОВИЋ2, ДРАГАНА П. СРЕБРО2, СОЊА 
M. ВУЧКОВИЋ2, МИЛОВАН Д. ИВАНОВИЋ3 и СЛАЂАНА В. КОСТИЋ-РАЈАЧИЋ1 
1ИХТМ - Центар за хемију, Универзитет у Београду, Његошева 12, 11000 Београд, 2Департман за 
фармакологију, клиничку фармакологију и токсикологију, Медицински факултет, Универзитет у 
Београду, Др Суботића 1/ III, 11000 Београд и 3Хемијски факултет, Универзитет у Београду, 
Студентски трг 12–16, 11000 Београд 
У овом раду је приказана синтеза и фармаколошко испитивање 13 нових једињења, 
дизајнираних са циљем да буду потенцијални бивалентни лиганди за μ-опиоидни рецеп-
тор (MOR) и допамински D2 рецептор (D2DAR). Једињења се састоје од анилидо-пипери-
динских (МОR фармакофора) и N-арилпиперазинских остатака (D2DAR фармакофора), 
повезаних метиленским ланцем променљиве дужине. Синтеза је обухватала четири 
корака, обезбеђујући крајње производе у укупним приносима од 28 до 42 %. Афинитет 
везивања за D2DAR одређен је in vitro тестом компетиције користећи [3H] спиперон као 
стандардни радиолиганд док је антиноцицептивна (опиоидна) активност испитана in vivo 
антиноцицептивним тестом. Активности новосинтетисаних једињења ка D2DAR биле су 
умерене до ниске, док је антиноцицептивна активност у потпуности изостала. 
(Примљено 12. септембра, ревидирано 25. октобра, прихваћено 31. октобра 2019) 
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